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Expansion of chemical space for
collaborative lead generation and drug
discovery: the European Lead Factory
PerspectiveAnna Karawajczyk1, Fabrizio Giordanetto1, Jorg Benningshof2, Daniel Hamza3, Tuomo Kalliokoski4,
Kees Pouwer5, Remy Morgentin6, Adam Nelson7,8, Gerhard Mu¨ller2, Alexander Piechot1 and
Dimitrios Tzalis1, dtzalis@taros.deHigh-throughput screening (HTS) represents a major cornerstone of drug discovery. The availability of
an innovative, relevant andhigh-quality compound collection to be screened often dictates the final fate
of a drug discovery campaign. Given that the chemical space to be sampled in research programs is
practically infinite and sparsely populated, significant efforts and resources need to be invested in the
generation and maintenance of a competitive compound collection. The European Lead Factory (ELF)
project is addressing this challenge by leveraging the diverse experience and know-how of academic
groups and small and medium enterprises (SMEs) engaged in synthetic and/or medicinal chemistry.
Here, we describe the novelty, diversity, structural complexity, physicochemical characteristics and
overall attractiveness of this first batch of ELF compounds for HTS purposes.Introduction
The continuing discovery and development of
novel, safe and effective medicines is expected
by contemporary society. Nevertheless, the in-
tellectual, technical and financial challenges
associated with it are enormous. Despite the
approval of 41 new therapeutics during 2014
(a significant 17-year high) [1], the ability of the
pharmaceutical industry to rise to these formi-
dable challenges is periodically questioned and
tentative solutions are constantly suggested [2–
7]. As a result, the field of drug research has seen
significant changes over the past decades and a
stronger emphasis on precompetitive, open-
source models is evident [8]. One such approach,1310 www.drugdiscoverytoday.com
1359-6446/ 2016 The Authors. Pthe European Lead Factory (ELF) a project of the
Innovative Medicine Initiative, has recently cre-
ated a collaborative lead generation platform to
boost the early phases of drug discovery [9]. The
state-of-the-art high-throughput screening (HTS)
infrastructure and the industrial-quality Joint
European Compound Collection of the ELF are
made available at no cost to European research
investigators, with a milestone payment system
applied to any exploitation projects targeting
commercialization (https://www.europeanlead-
factory.eu/#). As part of the ELF open-source
model, seven pharmaceutical companies (Bayer,
AstraZeneca, UCB, Lundbeck, Sanofi, Merck, J&J)
have contributed a total of 321,000 compoundsublished by Elsevier Ltd. This is an open access article under the CC BYfrom their proprietary collections [10]. This initial
set is now being complemented with up to an
additional 200,000 compounds [here termed the
Public Compound Collection (PCC)] in a collabo-
rative effort involving a unique blend of chemistry
expertise from ten academic groups and six small
andmedium enterprises (SMEs) (Table 1) building
the ELF Chemistry Consortium.
The goal of the PCC compounds is to populate
new, biologically relevant chemical spaces that
are typically not addressed in traditional
screening collections from chemical vendors or
corporate collections. This newly designed col-
lection is based on proposals for libraries of
compounds that are submitted by academic and-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.09.009
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TABLE 1
Chemistry-focused academic groups and SMEs participating to the ELF
Country Website
Academic Institution (principal investigator)
Max Planck Institute of Molecular Physiology
(Herbert Waldmann and Kamal Kumar)
Germany http://www.mpi-dortmund.mpg.de/74682/Kumar
Netherlands Cancer Institute (Huib Ovaa) The Netherlands http://www.nki.nl/divisions/cell-biology-ii/ovaa-h-group/
Technical University of Denmark (Mads Clausen) Denmark http://www.kemi.dtu.dk/english/Research/OrganicChemistry/Kemisk_Biologi/
MadsHClausenIntro
University of Duisburg-Essen (Markus Kaiser) Germany https://www.uni-due.de/zmb/members/kaiser/overview.shtml
University of Groeningen (Alexander Do¨mling) The Netherlands http://www.rug.nl/staff/a.s.s.domling/
University of Leeds (Adam Nelson and
Steve Mardsen)
UK http://www.chem.leeds.ac.uk/People/Nelson.html; http://www.chem.leeds.ac.uk/
People/Marsden.html
University of Leiden (Mario van der Stelt) The Netherlands http://biosyn.lic.leidenuniv.nl/people/vanderstelt
University of Nijmegen (Floris Rutjes) The Netherlands http://www.soc.science.ru.nl/index.php/people?view=member&id=1
University of Nottingham (Robert Stockman
and Chris Moody)
UK http://www.nottingham.ac.uk/chemistry/people/robert.stockman;
http://www.nottingham.ac.uk/Chemistry/People/c.j.moody
VU University of Amsterdam (Romano Orru) The Netherlands http://www.chem.vu.nl/en/research/division-organic-chemistry/staff/orru/index.asp
SME
Edelris France http://www.edelris.com
Lead Discovery Center Germany http://www.lead-discovery.de
Mercachem The Netherlands http://www.mercachem.com
Sygnature Discovery UK http://www.sygnaturediscovery.com
Syncom The Netherlands http://www.syncom.nl
Taros Germany http://www.taros-discovery.com
BOX 1
ELF library proposals parameters and measures.
Novelty: no matches against the existing JECL collection, previously accepted JECL libraries,
a collation of commercial vendor sources (http://www.int-conf-chem-structures.org/
fileadmin/user_upload/ICCS_2014/posters/P22-Kalliokoski.pdf ), and additional chemistry-
oriented repositories based on the patent literature [14].
Molecular properties: contemporary drug-like properties [15].
Diversity potential: number of diversification points (at least two) and their practical
exploitation.
Structural features: absence of chemical liabilities as defined by a collection of
substructure filters contributed by the pharmaceutical companies participating in the ELF
[10].
Synthetic tractability: cost of goods, atom economy, length and efficiency of the synthetic
route, and associated purification and diversification steps.
Innovation: original library design (structural and synthetic levels) rationale and concept.
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the consortium) adhering to strict quality
workflows in termsofdesign, chemistry validation
and production. Here, we describe the initial
batch of PCC screening compounds delivered by
the ELF Chemistry Consortium during the first 18
months of chemistry activities. These com-
pounds are compared to the Maybridge
Screening Collection (http://www.maybridge.
com/portal/alias__Rainbow/lang__en/
tabID__146/DesktopDefault.aspx), the collection
of the Molecular Library Program (MLP) of the
National Institutes of Health (NIH) [11] and com-
pounds curated in the ChEMBL database [12]. The
Maybridge collection was chosen as a represen-
tative screening library from commercial sources
because of its diversity-based character and
previous use in screening collections comparisons
[13]. The MLP library was selected because of the
similar collaborative nature of the MLP and ELF
programs, and the ChEMBL database because of
the medicinal chemistry relevance of the com-
pounds curated therein.
ELF library workflow
Library proposals submitted to the ELF Chem-
istry Consortium using a specifically designed
web-tool (https://www.europeanleadfactory.eu/
proposals/chemical-scaffolds/submit-your-
library-design-proposal/) are reviewed by a Li-
brary Selection Committee (LSC) comprising
eight experienced synthetic and medicinal
chemists from pharmaceutical companies,
SMEs, academic groups and screening centersadhering to the ELF project. Each proposal is
assessed against six specific criteria, as summa-
rized in Box 1. The novelty requirements need to
be met by all libraries to maximize coverage of
novel chemical space. Deviations from the
defaults of other parameters (e.g. molecular
properties or structural filters) are considered by
the LSC especially when a strong design concept
(e.g. natural product inspiration or target class
focus) is provided. The LSC final assessment is
then fed back to the library proposer to guide
the refinement of future submissions.
The accepted library proposals are then
evaluated experimentally by academic and in-
dustrial ELF consortium partners to verify
whether the intended libraries can be effectively
produced within the ELF project timeline and
budget. These library validation activities define
optimal conditions for crucial synthetic andpurification steps, and provide experimental
proof of their scalability and robustness to di-
versity. The chemical stability of intermediates
and final compounds is also monitored
throughout the course of library validation ac-
tivities. The experimental documentation is
reviewed by a Validation Committee that
ensures selected libraries are meeting the
practical requirements for production.
Successfully validated ELF libraries are then
further refined before production to maximize
their diversity, optimize properties, and ensure
novelty against public and commercial com-
pound sources and the growing number of PCC
compounds (http://www.int-conf-chem-
structures.org/fileadmin/user_upload/
ICCS_2014/posters/P22-Kalliokoski.pdf ). The
validated synthetic protocol is then executed
to standard industrial specifications. Librarywww.drugdiscoverytoday.com 1311
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FIGURE 1
Evaluation of inter-and intra-collection similarity. (a) Compound and library level descriptive statistics for the Public Compound Collection (PCC) library. Frequency
histograms of nearest neighbor molecular similarities, as measured by Tanimoto coefficients based on extended connectivity fingerprints (ECFP6) for: (b) PCC
compounds, (c) PCC and Maybridge compounds, (d) PCC and Molecular Library Program (MLP) compounds and (e) PCC and ChEMBL compounds.
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pound Library (JECL) quality criteria for purity
(LC–MS purity>85%) and quantity (>5 mmol) are
then added to the JECL andplated for theELFHTS.
The ELF compound management groups rou-
tinely perform standard sample analyses to
monitor compound purity, solubility and struc-
tural identity, and ensure adequate sample quality
for biological screening purposes. The synthe-
sized amounts have been defined so that each
sample is available to all HTS campaigns and
relevant follow-up activities during the course of
the ELF project, without the need for its resyn-
thesis. Additionally, each principal investigator
who receives a qualified hit-list at the end of an
ELFHTS andhit evaluation campaign could access
the relevant physical samples and associated
synthetic procedures for the compounds in the
qualified hit-list to jump-start additional research
efforts. Each hit compound appearing on such
qualified hit-lists will be automatically removed
from the JECL collection, as a way to protect the
intellectual property of the principal investigator.
Data sharing across the various ELF chemistry
consortium partners, from the original library
enumeration performed by the Lead Discovery
Center, to experimental validation procedures
from academic and SME groups, to the shipment
of the final compounds to the screening centers
from each SME, is facilitated by Tarosgate, a
chemistry management solution especially
designed for the ELF project.
Compound-level analysis
A total of 54,831 final compounds has been
successfully delivered to the ELF compound1312 www.drugdiscoverytoday.commanagement facilities and distributed to the ELF
screening centers, with an average LC–MS purity
of 97% and average 16 mmol amount, as de-
tailed in Fig. 1. Industrial and academic chemists
have designed and validated libraries that con-
tributed 57% and 43% of these compounds,
respectively. Overlap analysis of the screening
collections considered here reveals the PCC set
to be unique, with no duplicate structures
identified in the Maybridge collection, the MLP
or ChEMBL.
Compounds in the PCC set are also structurally
dissimilar to each other, as summarized in Fig. 1.
Here, the average Tanimoto coefficient based on
extended connectivity fingerprints (ECFP6) is
0.17. As a reference, compounds in the diversity-
based Maybridge library have a maximum
Tanimoto coefficient of 0.2 when using the same
ECFP6 metric. Furthermore, the PCC compounds
are significantly dissimilar from existing com-
pounds in the other collections considered in the
present study. Intercollection similarity is less
than 0.2 for the PCC set compounds when
compared with MPL-NIH, Maybridge and the
ChEMBL database, as described in Fig. 1.
The distributions of molecular descriptors
commonly used in medicinal chemistry are
shown in Fig. 2 for the PCC set, the Maybridge
screening collection, the MLP library and the
ChEMBL compound bank. Overall, all libraries
share typical Lipinski rule-of-five [14] attributes.
Here, the PCC library displays the highest polarity
and molecular weight. In total, 85% of the PCC
compounds have c log P values less than 4
compared with 80% for MLP, 62% for Maybridge
and 67% for ChEMBL compounds. In addition,58% of the PCC compounds have a molecular
mass greater than 400 Da (MLP, 30%; Maybridge,
21%, ChEMBL, 46%). The major differences be-
tween the libraries emerge when the number of
chiral centers and the fraction of sp3 hybridized
carbon atoms (Fsp3) are considered. 85% of the
PCC compounds are chiral with 62% of them
having two or more chiral centers (cf. Maybridge,
3%; MLP, 9% and ChEMBL, 22%). PCC com-
pounds also have an increased 3D character,
with 68% displaying Fsp3 greater than 0.4 (cf.
Maybridge, 15%; MLP, 29% and ChEMBL, 34%).
This translates as a marked difference at a mo-
lecular-shape level. When the 3D conformations
of the final compounds were analyzed using the
molecular principal moments of inertia (PMI) [15]
and plane of best fit (PBF) [16] methods (see the
supplementary material online), PCC com-
pounds demonstrated a significantly less flat and
more globular (‘sphere-like’) shape compared
with compounds in any of the databases eval-
uated in the present study (Fig. 2).
Scaffold level analysis
The PCC compounds originate from a total of
106 library proposals, yielding an average size of
library of 521 compounds (Fig. 1). Each library
proposal is normally defined by a scaffold, that is,
a molecular template that is chemically modified
in a systematic fashion at given positions (di-
versity points). Of the 106 unique PCC scaffolds,
73 (69%) contain at least three diversity points
that have been derivatized during library pro-
duction (Fig. 3). Most PCC scaffolds tend to be
compact (80% with molecular weight <200 Da)
and polar (70% with TPSA of 40–80 A˚2).
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FIGURE 2
Comparitive inter-and intra-collection compound collection analysis. (a)Molecular weight, (b) calculated log P (c log P), (c) number of chiral centers, (d) number
of rotatable bonds, (e) topological polar surface area (TPSA) and (f) fraction of sp3-hybridized carbon atoms profiles for Public Compound Collection (PCC) (red
bars), Molecular Library Program (MLP) (black bars), Maybridge (dark-gray bars) and ChEMBL (light-gray bars) compounds. Cumulative distributions of distances
from canonical sphere (g) and flat (h) shapes using principal moments of inertia (PMI) and plane of best fit (PBF) descriptors, respectively, for PCC (red diamonds),
MLP (black circles), Maybridge (dark-gray squares) and ChEMBL (light-gray triangles) compounds.
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scaffolds are mostly sp3 hybridized (Fsp3 > 0.4
for 86% of the PCC library cores) and two ormore
chiral atoms are present in 70% of their struc-
tures, as shown in Fig. 3. The structural similarity
among scaffolds is also low, with average and
maximum Tanimoto coefficients of 0.09 and 0.5,
respectively (Fig. 3f ).
Framework level analysis
Bemis–Murcko [17] scaffold analysis (see the
supplementarymaterial online) was then used to
evaluate the 2D shape and topology of the PCC
compounds. These are described by a total of
366 unique frameworks. Overlap analysis of the
frameworks across the different compound setsstudied here indicated that only 27% of the PCC
frameworks (N = 99) are shared across the PCC,
Maybridge, NIH and ChEMBL collections. Inter-
estingly, 56% of the PCC frameworks (N = 204)
are unique, as detailed in Fig. 4.
Discussion
After an initial preparatory phase dedicated to
recruitment, infrastructure set-up, workflow
evaluation and trust building, the ELF chemistry
consortium is now fully operational and actively
working toward the goal of synthesizing circa
200,000 novel, attractive compounds for bio-
chemical HTS purposes by the end of 2017. As of
March 2015, this had resulted in the successful
synthesis, purification and delivery of 54,831final compounds to the ELF screening centers. As
described here, the delivered samples are well
suited for HTS applications, being available in
sufficient quantities to allow up to 240 HTS
campaigns to be executed without sample de-
pletion and in outstanding chemical purity, thus
reducing the occurrence of screening false
positives and greatly simplifying results inter-
pretation, deconvolution and decision making
during hit evaluation.
The PCC compounds originate from a library-
based approach where congeneric series of
compounds are obtained through derivatization
of a common scaffold. Selection of diversity
reagents in the ELF aims at ensuring a good
balance between the availability of relatedwww.drugdiscoverytoday.com 1313
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FIGURE 3
Phys. Chem. properties at the scaffold Level. (a) Molecular weight, (b) number of chiral atoms, (c) number of diversity points, (d) topological polar surface area
(TPSA), (e) fraction of sp3-hybridised carbon atoms and (f) ECFP6-based Tanimoto similarity profiles for Public Compound Collection (PCC) scaffolds (N = 106).
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relationships (SAR) during hit evaluation and
wide sampling of chemical space. Accordingly,
the PCC compounds have a low level of struc-
[(Figure_4)TD$FIG]FIGURE 4
Bemis-Murcko Frameworks. (a) Number of Bemis–Mur
Collection (PCC) and overlapping with the Maybridge
compound sets. (b) Representative selection of Bemi
compounds. The Bemis–Murcko frameworks used in th
all heteroatoms have beenmutated to carbons, to incre
heteroatomic composition.
1314 www.drugdiscoverytoday.comtural redundancy, as measured by nearest
neighbor similarity, which is comparable to that
observed in the Maybridge set, a diversity-based
collection in the strictest sense. Importantly, thiscko frameworks unique to the Public Compound
, Molecular Library Program (MLP) and ChEMBL
s–Murcko frameworks unique to the PCC
e current analysis do not regard atom types, and
ase the focus on topological diversity rather thandegree of structural dissimilarity at a final
compound level is also observed at a scaffold
level. All the library scaffolds synthesized thus far
differ significantly from each other, and this
further increases the structural diversity and
chemical space coverage of the PCC set.
Although preferred extents of physicochemi-
cal properties in drug discovery applications are
a matter of debate, these are monitored
throughout the ELF process. As a result, the
profile of the PCC compounds does not signifi-
cantly deviate from commonly accepted prop-
erties trends in the field [14,18]. Here, a focus on
maintaining a low lipophilicity character is evi-
dent because of its perceived importance in the
subsequent hit development and lead optimi-
zation phases. This is especially important given
that a significant portion (45%) of the PCC
compounds have molecular weight of 400–
500 Da. Some of these compounds are aiming at
addressing challenging target classes (e.g. pro-
tein–protein interactions) with innovative che-
motypes. Complex natural products have also
been used as starting points for library design,
thus intrinsically increasing the weight of the
resulting compounds. In an effort to maximize
the structural diversity of each library, the ELF
consortium has been favoring designs with three
or more diversification points, which has also
yielded compounds with a modest increase in
weight. Nevertheless, it is anticipated that re-
duced lipophilicity could also be beneficial in
these higher molecular weight instances.
Drug Discovery Today  Volume 20, Number 11 November 2015 PERSPECTIVE
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PCC set is their high level of structural complexity
and three-dimensionality, two features that are
regarded as attractive in drug discovery applica-
tion [19,20]. Given that most PCC compounds are
chiral molecules with nonaromatic, nonplanar
moieties and a strong propensity for a globular
shape, their systematic screen against biological
systemswill prove useful in further understanding
the general relevance of such compound char-
acteristics, especially when confirmed hit rates,
target class and developability considerations
are taken into account. When comparing final
compounds and scaffolds profiles, it is inter-
esting to note that the polarity, structural
complexity and 3D elements have been engi-
neered in the scaffolds rather than deriving
entirely from the subsequent chemical deco-
ration. Given that the PCC scaffolds tend to be
small, polar and chiral with a high 3D character,
they provide versatile starting points and ample
opportunities for further chemical exploration
and growth during the hit-to-lead phase, based
on the specific biological target and/or thera-
peutic area requirements.
A strong focus of the ELF chemistry con-
sortium is to populate areas of chemical space
that are not directly accessible from commer-
cial sources or the scientific literature. Thus, no
structural overlap with the Maybridge, MLP or
ChEMBL databases is observed. Importantly,
the similarity of the PCC compounds to any of
the collections analyzed here is also limited,
highlighting the complementary nature of the
PCC compounds in terms of chemical space
distribution. The high novelty attribute of the
PCC compounds is also apparent when
structural shape and topology is considered. A
large proportion of the PCC frameworks are
absent in the compound collections analyzed
here. Indeed, a significant number of unprec-
edented spiro, bridged and fused polycycles
with different degrees of saturation, conjuga-
tion and substitution have been synthesized
and expanded to a library format. This has been
recently exemplified by several
publications from the ELF chemistry groups
detailing the associated design and validation
aspects [21–38]. Given that most theoretical
ring systems remain unexplored [39], the syn-
thesis of novel rings represents one of the
strategies embraced by the ELF chemistry
consortium to expand the available chemical
space.
Concluding remarks
Given that large-scale screening continues to be
a practical and productive entry to successfuldrug discovery [40,41], the availability of a novel,
high-quality screening collection cannot be
emphasized enough [42]. During the past year
and a half of work, the ELF Chemistry Consortium
has implemented an innovative compound li-
brary factory based on a collaborative approach
between chemistry-focused academic groups
and SMEs. This has resulted in an effective
pooling of complementary ideas, solutions and
resources to carry out high-risk chemistry re-
search to explore unprecedented areas of
chemical space that are relevant to biological
screening. These efforts have yielded diverse and
distinctive compounds that will properly com-
plement existing public and proprietary com-
pound collections for HTS drug discovery
applications. Building on intersectoral, comple-
mentary strengths and expertise, this offers
a practical blueprint for future compound
collection enhancement campaigns in the ev-
erlasting quest for novel chemical space.
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